Chorioamnionitis and Proinflammatory S100A12 — S100A12  

Chorioamnionitis Affecting Fetus or Newborn Clinical Trial

Official title: Impact of Chorioamnionitis on Maternal and Fetal Levels of Proinflammatory S100A12

Status Completed

Clinical Trial Summary

Histologic chorioamnionitis (HCA) may lead to the fetal inflammatory response syndrome (FIRS) and increased levels of proinflammatory molecules.

Clinical Trial Description

Histologic chorioamnionitis (HCA) may lead to the fetal inflammatory response syndrome (FIRS). The aim of this pilot study was to evaluate S100A12, a marker of innate immune activation, in mothers with or without HCA and in their infants.

Concentrations of S100A12, Interleukin 6 (IL-6) and C-reactive protein (CRP) were evaluated in maternal, cord, and neonatal blood of very preterm infants. Histologic examinations of placentae and umbilical cords were performed. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Chorioamnionitis
• Chorioamnionitis Affecting Fetus or Newborn

• NCT number: NCT02996279
• Study type: Observational
• Source: Catholic University of the Sacred Heart
• Status: Completed
• Phase: N/A
• Start date: February 2012
• Completion date: March 2013